Valuation: Innoviva, Inc.

Market Cap 1.65B 1.44B 1.32B 1.23B 2.34B 157B 2.38B 15.91B 6.17B 76.89B 6.18B 6.05B 265B P/E 2026 *
6.68x
P/E 2027 * 9.75x
Enterprise Value 1.13B 990M 909M 848M 1.61B 108B 1.63B 10.94B 4.24B 52.89B 4.25B 4.16B 182B EV / Sales 2026 *
2.57x
EV / Sales 2027 * 1.89x
Free-Float
99.01%
Yield 2026 *
-
Yield 2027 * -
1 day+1.87%
1 week-4.45%
Current month-1.76%
1 month+4.50%
3 months-2.96%
6 months+12.28%
Current year+11.61%
1 week 21.7
Extreme 21.7
23.72
1 month 21.7
Extreme 21.7
24.17
Current year 19
Extreme 19
25.14
1 year 16.52
Extreme 16.52
25.14
3 years 12.22
Extreme 12.22
25.14
5 years 10.64
Extreme 10.64
25.14
10 years 7.58
Extreme 7.58
25.14
Manager TitleAgeSince
Chief Executive Officer 42 19/05/2020
Director of Finance/CFO 60 20/08/2023
Investor Relations Contact - 31/08/2025
Director TitleAgeSince
Director/Board Member 75 11/02/2018
Director/Board Member 66 11/02/2018
Director/Board Member 42 18/05/2025
Date Insider Type Main position Quantity % Market Cap.
05-19Tax

Chief Financial Officer

-559 0.0008%
05-19Tax

Controller/Auditor

-1,127 0.0015%
05-19Tax

Chief Executive Officer

-1,130 0.0015%
Change 5-day change 1-year change 3-year change Capi.($)
+1.87%-4.45%+15.00%+75.26% 1.65B
+1.86%+7.65%+55.77%+158.84% 1,082B
+3.57%+7.42%+69.09%+58.92% 633B
+3.99%+7.37%+36.87%+93.77% 461B
+2.95%-1.94%+26.41%+20.22% 339B
-0.89%+0.34%+40.79%+38.48% 301B
-0.38%+0.86%+31.57%+43.84% 292B
-1.68%+2.39%-25.66%-39.86% 225B
+3.55%+6.05%+26.04%+68.52% 202B
+4.21%+6.00%+17.72%+70.33% 163B
Average +1.42%+3.62%+29.36%+58.83% 370.14B
Weighted average by Cap. +1.28%+5.21%+41.61%+81.11%

Financials

2026 *2027 *
Net sales 441M 385M 353M 330M 625M 41.94B 636M 4.26B 1.65B 20.57B 1.65B 1.62B 70.88B 486M 425M 390M 364M 690M 46.27B 701M 4.7B 1.82B 22.7B 1.83B 1.79B 78.21B
Net income 286M 250M 229M 214M 406M 27.22B 412M 2.76B 1.07B 13.35B 1.07B 1.05B 46.01B 185M 162M 149M 139M 263M 17.62B 267M 1.79B 693M 8.64B 695M 680M 29.78B
Net Debt -514M -449M -412M -385M -729M -48.94B -742M -4.97B -1.92B -24B -1.93B -1.89B -82.71B -728M -637M -585M -545M -1.03B -69.35B -1.05B -7.04B -2.73B -34.01B -2.74B -2.68B -117B
Logo Innoviva, Inc.
Innoviva, Inc. is a diversified holding company with a portfolio of royalties and other healthcare assets. The Company's royalty portfolio consists of respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, FF/VI) and ANORO ELLIPTA (umeclidinium bromide/vilanterol, UMEC/VI). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement, the Company is entitled to receive royalties from GSK on sales of RELVAR/BREO, ELLIPTA. The Company's products include GIAPREZA (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock, and XERAVA (eravacycline) approved for the treatment of complicated intra-abdominal infections in adults. The third product, XACDURO (formerly known as sulbactam-durlobactam or SUL-DUR), is approved for the treatment of hospital-acquired and ventilator-associated pneumonias caused by Acinetobacter in adults. The development pipeline includes zoliflodacin, an investigational treatment for uncomplicated gonorrhea is in Phase III clinical trial.
Employees
159
Date Price Change Volume
02/07/26 US$22.31 +1.87% 655,045
01/07/26 US$21.90 -3.57% 786,905
30/06/26 US$22.71 -1.86% 633,019
29/06/26 US$23.14 -1.82% 879,063
26/06/26 US$23.57 +0.94% 2,834,672
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
22.31USD
Average target price
35.50USD
Spread / Average Target
+59.12%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. INVA Stock